Lymphoma PDX Models

Identifying robust preclinical models for lymphoma is essential for the development of new therapies targeting this disease. Patient Derived Xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity providing an accurate approach to predicting an agent’s efficacy prior to entering the clinic. The CrownBio lymphoma PDX collection consists of many models, including both primary and metastatic models. More

Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL ID CANCER TYPE SUBTYPE models per page
LY0257 Lymphoma NHL (DLBCL, ABC, MYD88 L265P) VIEW MODEL Details
LY14019 Lymphoma NHL VIEW MODEL Details
LY2118 Lymphoma EBV transformed lymphoma VIEW MODEL Details
LY2214 Lymphoma NHL (DLBCL, GCB) VIEW MODEL Details
LY2219 Lymphoma EBV transformed lymphoma VIEW MODEL Details
LY2240 Lymphoma EBV transformed lymphoma VIEW MODEL Details
LY2264 Lymphoma NHL (DLBCL, ABC, MYD88 L265P) VIEW MODEL Details
LY2266 Lymphoma NHL (B cell, ABC/GCB) VIEW MODEL Details
LY2298 Lymphoma B cell lymphoma (ABC/GCB, MYD88 L265P) VIEW MODEL Details
LY2301 Lymphoma NHL (DLBCL, ABC) VIEW MODEL Details